Piper Sandler analyst Jessica Tassan maintains $Alignment Healthcare (ALHC.US)$ with a buy rating, and adjusts the target price from $10 to $14.
According to TipRanks data, the analyst has a success rate of 40.8% and a total average return of -3.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Alignment Healthcare (ALHC.US)$'s main analysts recently are as follows:
Alignment Healthcare's performance in Q3 was notable for its revenue growth, SG&A leverage, and overall profit. This quarter's results have bolstered confidence in the company's potential for a profitability turning point.
Following the Q3 report, it's noted that increased medical loss ratio guidance due to new member growth and clinical initiatives has led to a slight reduction in the 2024 EBITDA forecast.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
